Z-2460-2026 Class II Ongoing
FDA device recall Z-2460-2026 was initiated by Accriva Diagnostics, Inc. on Apr 30, 2026 and is designated Class II. Reason for recall: Assayed Whole blood control contains labeling with incorrect performance range. The recall status is ongoing. Affected quantity: 6060.
Recall details
- Product Type
- Devices
- Report Date
- Jun 24, 2026
- Initiation Date
- Apr 30, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 6060
Product description
directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2
Reason for recall
Assayed Whole blood control contains labeling with incorrect performance range.
Distribution pattern
Worldwide - US Nationwide distribution including in the states of AL, AR, AZ, CA, FL, GA, ID, IL, IN, KY, MA, MD, MI, MN, MO, MT, NC, NJ, NM, NY, OH, OK, PA, SC, TN, TX, VA, VT, WA, WI, WV and the countries of Canada, Hong Kong, Spain.
Code information
Lot #: A6DLA001 Unique Device Identifier: 10711234170373
Source
- Dataset
- openFDA device recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for Z-2460-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026